Vaxcyte
56.15
+2.24
+4.16%
PCVX
02-06 16:00:00(美东时间)
高
56.45
开
55.16
量
108.08万股
总市值
80.61亿
低
54.32
换
0.75%
额
6033.02万
市盈TTM
亏损
分时
5日
日K
周K
月K
季K
年K
MA
BOLL
成交量
MACD
KDJ
RSI
WR
BIAS
CCI
PSY
讨论
资讯
公告
资料
财务
相关
成分股
Vaxcyte(PCVX)
01-17 06:15
$Vaxcyte(PCVX)$
4 Statement of changes in beneficial ownership of securities Accession Number: 0001230724-26-000002 Size: 7 KB
网页链接
Vaxcyte(PCVX)
01-17 06:15
$Vaxcyte(PCVX)$
4 Statement of changes in beneficial ownership of securities Accession Number: 0001508518-26-000002 Size: 7 KB
网页链接
Vaxcyte(PCVX)
2025-12-20 05:15
$Vaxcyte(PCVX)$
8-K Current report, items 5.02 and 9.01 Accession Number: 0001649094-25-000116 Act: 34 Size: 166 KB
网页链接
Vaxcyte(PCVX)
01-01 05:35
$Vaxcyte(PCVX)$
144 Report of proposed sale of securities Accession Number: 0001950047-25-010785 Act: 33 Size: 10 KB
网页链接
Vaxcyte(PCVX)
01-30 05:05
$Vaxcyte(PCVX)$
424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-26-029298 Act: 33 Size: 681 KB
网页链接
麻辣小龙虾呀
02-03 17:00
$Vaxcyte(PCVX)$
很稳的肺炎疫苗股票,就是催化点要到年底了。
Vaxcyte(PCVX)
2025-11-15 01:25
$Vaxcyte(PCVX)$
SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors Accession Number: 0001897612-25-000545 Act: 34 Size: 7 KB
网页链接
Vaxcyte(PCVX)
01-03 05:25
$Vaxcyte(PCVX)$
4 Statement of changes in beneficial ownership of securities Accession Number: 0001886794-26-000002 Size: 5 KB
网页链接
Vaxcyte(PCVX)
02-03 05:05
$Vaxcyte(PCVX)$
8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-26-033578 Act: 34 Size: 452 KB
网页链接
Vaxcyte(PCVX)
01-31 06:15
$Vaxcyte(PCVX)$
424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-26-032045 Act: 33 Size: 786 KB
网页链接
Vaxcyte(PCVX)
2025-11-15 01:05
$Vaxcyte(PCVX)$
SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001274173-25-000292 Act: 34 Size: 9 KB
网页链接
Vaxcyte(PCVX)
2025-12-30 06:55
$Vaxcyte(PCVX)$
4 Statement of changes in beneficial ownership of securities Accession Number: 0001960048-25-000010 Size: 8 KB
网页链接
Vaxcyte(PCVX)
01-17 06:15
$Vaxcyte(PCVX)$
4 Statement of changes in beneficial ownership of securities Accession Number: 0001258693-26-000002 Size: 6 KB
网页链接
Vaxcyte(PCVX)
2025-12-24 05:05
$Vaxcyte(PCVX)$
144 Report of proposed sale of securities Accession Number: 0001950047-25-010646 Act: 33 Size: 9 KB
网页链接
维诺格拉多夫
01-23 16:32
生物科技公司Vaxcyte Inc.(NASDAQ: VCYT)宣布其下一代肺炎疫苗在临床开发方面取得重大进展,有望按计划向监管机构提交生物制品许可申请(BLA)。该公司3期临床试验数据显示,疫苗在多个年龄组中均达到主要终点。
公司管理层表示,该疫苗有潜力满足全球免疫接种中的未满足需求,特别是在高危...
药智网
02-04 10:49
当Vaxcyte将其31价肺炎结合疫苗VAX-31推入三期临床,一场围绕“价数”的疫苗竞赛已进入白热化。
01
技术路线之争
肺炎疫苗领域的市场竞争核心聚焦于技术创新突破,传统多价肺炎疫苗在研发进程中,始终受限于价态提升与免疫原性同步增强的矛盾困境,价态增加常伴随免疫原性衰减现象...